Elevated LOXL2 expression in estrogen receptor-negative breast tumors is strongly associated with unfavorable outcomes, including poor prognosis, decreased overall survival, and reduced metastasis-free survival, suggesting that LOXL2 could serve as a valuable prognostic marker for metastasis in breast cancer cases. The gene discussed is ESR1; the disease is breast cancer.